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C
olorectal cancer screening works! We have convincing
evidence from randomized trials of fecal occult blood
tests (FOBT) showing that colorectal cancer screening reduces
disease-specific morbidity and mortality
1. Case-control studies
suggest that endoscopy is also effective
2–4. Nonetheless, only
about 60% of eligible adults are currently screened for
colorectal cancer
5. In contrast, nearly 75% of women are
currently screened for breast cancer
6, which has a similar
level of evidence for efficacy as colorectal screening. More than
70% of men are currently screened for prostate cancer, which
has uncertain efficacy
7. The discordance between evidence and
uptake of colorectal cancer screening has sparked consider-
able efforts to increase screening rates. However, the report by
Kahi and colleagues suggests that these efforts may have the
unintended consequence of promoting screening recommen-
dations that fail to adequately consider the risks and benefits
of screening in the context of a patient′s health status and life
expectancy
8.
Perhaps cancer screening is like the forward pass in
football. Darrell Royal the legendary coach at the University
of Texas has said, “When you throw a pass, only three things
can happen, and two of ‘em are bad.” Colorectal cancer
screening can reduce morbidity and mortality, the supreme
accomplishment of a screening program. However, the abso-
lute benefit to a screened population is small; most people will
not benefit because they do not have early-stage colorectal
cancer or polyps destined to become malignant. The Minnesota
Colon Cancer Control Study showed that annual FOBT
screening reduced colorectal cancer mortality by about 3
deaths per 1000 people screened after 13 years of follow up
9.
Similarly, screening reduced the risk for cancer diagnosis by
just 7 per 1,000 people screened after 18 years of follow up
10.
This small likelihood of future benefit must then be weighed
against the more immediate potential downsides of screening,
including false positive tests, the costs and risks of invasive
diagnostic tests, treatment complications, and the risk for
overdiagnosing cancer—finding disease that is not destined to
cause any problems during a patient′s lifetime.
The latter problem is particularly pertinent for cancer
screening in sick and elderly patients. To minimize inappro-
priate and potentially harmful screening, the US Preventive
Services Task Force has recently provided explicit guidelines—
no screening after age 85 and personalized screening decisions
for those ages 76 to 85
11. These recommendations are partly
based on the trial data showing that colorectal cancer
survival curves did not diverge until 5 years after the start
of screening. This interval reflects that it often takes many
years between when a cancer could be first detectable by
screening until when it would have grown large enough to
cause symptoms or death. The recommendation for “person-
alized” screening decisions really is a call for informed
decision making. Older patients, especially those who have
serious medical illnesses, need to be aware that they are
least likely to live long enough to receive any benefit from
cancer screening and more likely to experience the complica-
tions from tests and treatments.
The study by Kahi and colleagues did not address whether
physicians would elicit patient preferences or support in-
formed decision-making, but the fact that respondents
reported that they would offer screening to patients over age
85 or to 75-year-old patients with cancers or severe heart
failure is disconcerting. These patients clearly are very unlikely
to derive any benefit from screening and are at substantial risk
for being harmed. While these are survey data and respon-
dents were presented with hypothetical scenarios, it appears
that actual screening practices may indeed be quite inappro-
priate. A recent cohort study of older veterans at four VA
medical centers used linked VA and Medicare data to describe
screening practices
12. During calendar years 2001 and 2002,
3 7 . 6 %o fv e t e r a n sa g e d8 0a n do l d e rw h ow e r ed u ef o r
colorectal cancer screening underwent screening with FOBT,
endoscopy, or barium enema. Strikingly, among this group,
the screening rate was 34% for those with severe comorbidity
(defined by Charlson–Deyo scores ≥ 4), only slightly lower than
the 38% screening rate for those who had comorbidity scores
of 0.
Why is this happening? Several authors have suggested that
organizational zeal to boost screening rates by converting
practice guidelines into performance measures can increase
the rate of inappropriate screening in the sick and elderly
13,14.
Similarly, public service messages targeting the public may
oversimplify the screening message—“just do it”—rather than
presenting accurate, balanced information about the pros and
cons of screening. Such oversimplified messages likely con-
tribute to why many patients do not make informed decisions
about cancer screening and why frail elderly patients continue
to undergo cancer screening, even when the risks are sub-
stantial and the benefits are remote.
What can be done about this? Clearly, organizations need to
more carefully balance performance measures and financial
incentives with evidence-based guidelines. Quality-of-care
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1336assessments must identify and reward efforts that target
patients most likely to benefit from screening rather than
those efforts that merely increase screening rates. Optimizing
the targeting of cancer screening also may require changes in
how preventive care is delivered. The current system for
delivering preventive care relies on finding opportunities for
screening when patients see clinicians for medical problems,
which targets screening to elderly patients with more serious
comorbid conditions because they see clinicians more fre-
quently. This system misses healthy patients who see clini-
cians less frequently. In addition, both patients and clinicians
need to be more aware of the potential risks associated with
screening, especially for persons with advanced age and
serious comorbidities. When two out of three outcomes for
the forward pass are bad, the coach and players need to
carefully study the playbook and make an informed decision.
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